Opal Viewer Lite For Mac Download



Opal Viewer Lite For Mac DownloadOSIRIX (“THE SOFTWARE”) IS PROVIDED AS IS. USE THE SOFTWARE AT YOUR OWN RISK. THE AUTHORS MAKE NO WARRANTIES AS TO PERFORMANCE OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER WARRANTIES WHETHER EXPRESSED OR IMPLIED. NO ORAL OR WRITTEN COMMUNICATION FROM OR INFORMATION PROVIDED BY THE AUTHORS SHALL CREATE A WARRANTY. UNDER NO CIRCUMSTANCES SHALL THE AUTHORS BE LIABLE FOR DIRECT, INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES RESULTING FROM THE USE, MISUSE, OR INABILITY TO USE THE SOFTWARE, EVEN IF THE AUTHOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THESE EXCLUSIONS AND LIMITATIONS MAY NOT APPLY IN ALL JURISDICTIONS. YOU MAY HAVE ADDITIONAL RIGHTS AND SOME OF THESE LIMITATIONS MAY NOT APPLY TO YOU.Opal

THIS SOFTWARE IS NOT INTENDED FOR PRIMARY DIAGNOSTIC, ONLY FOR SCIENTIFIC USAGE.

THIS VERSION OF OSIRIX IS NOT CERTIFIED AS A MEDICAL DEVICE FOR PRIMARY DIAGNOSIS. THERE ARE NO CERTIFICATIONS. YOU CAN ONLY USE OSIRIX AS A REVIEWING AND SCIENTIFIC SOFTWARE, NOT FOR PRIMARY DIAGNOSTIC.

CERTIFIED VERSION OF OSIRIX IS AVAILABLE HERE: OSIRIX MD

Opal Viewer Lite Mac Free

All calculations, measurements and images provided by this software are intended only for scientific research. Any other use is entirely at the discretion and risk of the user. If you do use this software for scientific research please give appropriate credit in publications. This software may not be redistributed, sold or commercially used in any other way without prior approval of the author.

Lite

Opal Web Viewer Download

CNET Download provides free downloads for Windows, Mac, iOS and Android devices across all categories of software and apps, including security, utilities, games, video and browsers. Horos™ is a free, open source medical image viewer. The goal of the Horos Project is to develop a fully functional, 64-bit medical image viewer for OS X. Horos is based upon OsiriX and other open source medical imaging libraries. Horos is made available under.





Comments are closed.